Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLADIATOR: Long-term open-label safety study of lasmiditan for acute migraine
2015-005674-37Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lasmiditan in migraine (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety - proportion of patients with any adverse event, Safety - proportion of attacks with any adverse event and 2 more. Started Jul 2016; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on 2015-005674-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005674-37.